Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction

Pharmacogenomics Journal

Volumn 15, Issue 1, 2015, Pages 20-25

  Depta, J P ^a   Lenzini, P A ^a   Lanfear, D E ^b   Wang, T Y ^c   Spertus, J A ^d   Bach, R G ^a   Cresci, S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AFRICAN AMERICAN; ARTICLE; BLEEDING; CAUCASIAN; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART MUSCLE REVASCULARIZATION; HOMOZYGOTE; HOSPITAL READMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT HISTORY OF CORONARY ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; QUALITY CONTROL; SECONDARY PREVENTION; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNITED STATES; AGED; ANALOGS AND DERIVATIVES; GENETICS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; CYTOCHROME P-450 CYP2C19; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84921840460     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.28     Document Type: Article

References (32)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-e245.
2. Bhatt DL. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. Am J Cardiol 2009; 103: 11A-19A.
3. Depta JP, Bhatt DL. Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. Am J Cardiovasc Drugs 2008; 8: 91-112.
4. Somma KA, Bhatt DL, Fonarow GC, Cannon CP, Cox M, Laskey W et al. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Am J Cardiovasc Drugs 2012; 5: 654-661.
5. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
6. Depta JP, Bhatt DL. Antiplatelet therapy and proton pump inhibition: cause for concern? Curr Opin Cardiol 2012; 27: 642-650.
7. Depta JP, Bhatt DL. Omeprazole and clopidogrel: Should clinicians be worried? Cleve Clin J Med 2010; 77: 113-116.
8. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
9. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64: 935-951.
10. Frelinger 3rd AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol 2012; 59: 1304-1311.
11. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
12. O'Donoghue ML. CYP2C19 genotype and proton pump inhibitors in clopidogreltreated patients: does it take two to tango? Circulation 2011; 123: 468-470.
13. Arnold SV, Chan PS, Jones PG, Decker C, Buchanan DM, Krumholz HM et al. Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes 2011; 4: 467-476.
14. Cresci S, Wu J, Province MA, Spertus JA, Steffes M, McGill JB et al. Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial. Circulation 2011; 124: 1426-1434.
15. Lanfear DE, Jones PG, Cresci S, Tang F, Rathore SS, Spertus JA. Factors influencing patient willingness to participate in genetic research after a myocardial infarction. Genome medicine 2011; 3: 39.
16. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113.
17. Wang H, An N, Wang H, Gao Y, Liu D, Bian T et al. Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 40-hydroxylation and omeprazole 5'-hydroxylation. Drug Metab Dispos 2011; 39: 830-837.
18. Yan AT, Yan RT, Tan M, Eagle KA, Granger CB, Dabbous OH et al. In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. Am J Cardiol 2005; 96: 913-916.
19. Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J 2007; 153: 29-35.
20. Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica 2012; 42: 633-640.
21. Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos 2012; 40: 1698-1711.
22. Fernando H, Bassler N, Habersberger J, Sheffield LJ, Sharma R, Dart AM et al. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost 2011; 9: 1582-1589.
23. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70: 383-392.
24. Hulot JS, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard A, Peyrard S et al. Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost 2010; 8: 610-613.
25. Liu Q, Dang DS, Chen YF, Yan M, Shi GB, Zhao QC. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles. Genet Test Mol Biomarkers 2012; 16: 1293-1297.
26. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123: 474-482.
27. Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM et al. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19∗2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost 2011; 9: 1892-1901.
28. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1: 620-627.
29. Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008; 101: 1088-1093.
30. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest 2nd CS et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-2436.
31. Frere C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The CYP2C19∗17 allele is associated with better platelet response to clopidogrel in patients admitted for non- ST acute coronary syndrome. J Thromb Haemost 2009; 7: 1409-1411.
32. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87: 257-261.